Skip to content

Trial · Interventional

CompletedPhase 2Results postedRegistry data

A Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children Ages 6-17 Years Who Fulfill Modified Rome III Criteria for Child/Adolescent Functional Constipation (FC)

Overview

Status
Completed
Phase
Phase 2
Enrollment
173 participants (actual)
Sponsor
Forest Laboratories · Industry
Design
Randomized · Quadruple masking
Countries
2 countries

United States, Canada

Start
3 Nov 2015
Primary completion
20 Apr 2018
Completion
29 May 2018
First posted
24 Sept 2015 (estimated)
Last update posted
19 Jun 2019
Conditions
Functional Constipation in Children Ages 6-17 Years

Timeline

1 trial · 1 completed · 1 with posted results

  • Completed
  • Ongoing
  • Not yet recruiting
  • Stopped
  • Estimated dates (est.)
  • Results posted
20152016201720182019
  1. Ph 2

    A Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children Ages 6-17 Years Who Fulfill Modified Rome III Criteria for Child/Adolescent Functional Constipation (FC)

    NCT02559570

    3 Nov 2015 to 29 May 2018

Registry summary

Text and fields below are the sponsor's entries at ClinicalTrials.gov, shown as posted.

The purpose of this study was to evaluate dose response of the safety and efficacy of linaclotide for the treatment of functional constipation (FC), in children age 6-17 years. This study includes up to a 4-week Screening Period, and a 2 to 3-week Pretreatment Period. Participants age 6-11 years will receive oral liquid formulation and participants 12-17 years will receive solid oral capsule or liquid oral solution. Children ages 6-11 years meeting the entry criteria will be randomized to 1 of 3 doses of linaclotide or placebo for 4 weeks. Children ages 12-17 years meeting the entry criteria will be randomized to 1 of 4 doses of linaclotide or placebo for 4 weeks. This 4-week study will assess the effects of linaclotide on bowel movement frequency, as well as other bowel symptoms of FC.

Interventions

  • PlaceboDrug
  • LIN Dose ADrug
  • LIN Dose BDrug
  • LIN Dose CDrug
  • LIN 145 µgDrug

Arms5

  • Placebo comparator

    Placebo

    Participants aged 6 to 11 or 12 to 17 years received matching placebo linaclotide (LIN), 30 minutes before evening meal, once daily for 4 weeks. Administered as liquid oral solution for participants 6 to 11 years of age and solid oral capsule or liquid oral solution for participants 12 to 17 years of age.

  • Experimental

    LIN Dose A (9 ug or 18 ug)

    Participants aged 6 to 11 years with weight 18 to \<35 kg received LIN 9 ug, oral solution, 30 minutes before evening meal, once daily for 4 weeks. Participants aged 6 to 11 years with weight ≥35 kg received LIN 18 ug, oral solution, 30 minutes before evening meal, once daily for 4 weeks. Participants aged 12 to 17 years received LIN 18 ug, oral solution or solid capsules, 30 minutes before evening meal, once daily for 4 weeks.

  • Experimental

    LIN Dose B (18 ug or 36 ug)

    Participants aged 6 to 11 years with weight 18 to \<35 kg received LIN 18 ug, oral solution, 30 minutes before evening meal, once daily for 4 weeks. Participants aged 6 to 11 years with weight ≥35 kg received LIN 36 ug, oral solution, 30 minutes before evening meal, once daily for 4 weeks. Participants aged 12 to 17 years received LIN 36 ug, oral solution or solid capsules, 30 minutes before evening meal, once daily for 4 weeks.

  • Experimental

    LIN Dose C (36 ug or 72 ug)

    Participants aged 6 to 11 years with weight 18 to \<35 kg received LIN 36 ug, oral solution, 30 minutes before evening meal, once daily for 4 weeks. Participants aged 6 to 11 years with weight ≥35 kg received LIN 72 ug, oral solution, 30 minutes before evening meal, once daily for 4 weeks. Participants aged 12 to 17 years received LIN 72 ug, oral solution or solid capsules, 30 minutes before evening meal, once daily for 4 weeks.

  • Experimental

    LIN 145 µg

    Participants aged 12 to 17 years received LIN 145 ug, oral solution or solid capsules, 30 minutes before evening meal, once daily for 4 weeks.

Primary outcomes1

Outcomes the sponsor listed as primary.

  1. Change From Baseline (CFB) in 4-week Overall Spontaneous Bowel Movement (SBM) Frequency Rate During the Treatment Period

    Time frame · Baseline (14-day prior to randomization and up to randomization) to Week 4

    Registry description

    SBM was defined as a BM that occurred in the absence of laxative, suppository, or enema use on the calendar day of the BM or the calendar day before the BM. SBM rate was defined as SBMs/week during the 4-week Treatment period. Participants recorded the occurrence of BMs and use of rescue medication, morning and evening, daily in an eDiary since pretreatment period. The SBM frequency rate (SBMs/week) during the analysis period for each participant were calculated as \[(total number of SBMs in the analysis period/number of days in the analysis period)\*7\]. Baseline value was based on values collected 14 days before randomization up to randomization. Change from Baseline was calculated as the SBM frequency rate during the 4-week treatment period - SBM frequency rate at baseline. A positive change from Baseline indicates improvement. Least squares mean (LSM) and standard error (SE) were calculated using analysis of covariance (ANCOVA) method.

Secondary outcomes(6)
  1. Change From Baseline (CFB) in 4-week Daytime Abdominal Pain

    Time frame · Baseline (14-day prior to randomization) to Week 4

    Registry description

    The abdominal pain score was measured using 5-point scale. Participants answered the questions, How much did your tummy hurt as: 0=none, 1=a tiny bit, 2=a little, 3=some, and 4=a lot. The 4-week daytime abdominal pain was calculated as the average of nonmissing scores in evening eDiary during the Treatment Period with higher value indicating greater symptom severity. Baseline value was the average of non-missing values collected 14 days before randomization. Change from Baseline was calculated as the daytime abdominal pain score during the 4-week treatment period (i.e. average of non-missing daytime scores during 4-week treatment period) - daytime abdominal pain score at baseline. A negative change from Baseline indicates improvement. LSM and SE were calculated using ANCOVA method.

  2. Change From Baseline (CFB) in 4-week Stool Consistency

    Time frame · Baseline (14-day prior to randomization and up to randomization) to Week 4

    Registry description

    Participants used 7-point pediatric Bristol Stool Form (p-BSFS) scale to rate stool consistency for each BM in morning and evening eDiary where 1=small hard lumps or balls like pebbles,2=fat sausage shape but lumpy and hard,3=a sausage but with cracks on it,4=sausage or snake, smooth and soft,5=chicken nuggets, soft smooth blobs,6=oatmeal, fluffy mushy pieces,7=milkshake, watery. Scores in 4-week treatment period were calculated by 2 approaches-1) following derivation similar in earlier adult studies, mean of participants non-missing, SBM associated p-BSFS scores during 4-week treatment period (adult derivation),2) observed weighted average of daily p-BSFS scores during that period. Daily p-BSFS score was average of non-missing morning and/or evening assessments of p-BSFS score from SBMs reported by participants on that specific day. Baseline value was based on values collected 14 days before randomization up to randomization. LSM and SE were calculated using ANCOVA method.

  3. Change From Baseline (CFB) in 4-week of Severity of Straining

    Time frame · Baseline (14-day prior to randomization and up to randomization) to Week 4

    Registry description

    Severity of straining was scored on 5-point scale for question-When you pooped, how hard did you push? The score ranges from 0= not hard at all,1= I pushed a tiny bit hard,2= I pushed a little hard,3= I pushed hard,4= I pushed very hard with higher scores indicating more severe straining. Participants recorded degree of straining for each BM in morning and evening eDiary. Data was derived as adult derivation and weighted average. Scores during 4-week treatment period were calculated following two approaches - (1) following derivation similar in earlier adult studies, as mean of participant's non-missing, SBM associated straining scores during 4-week treatment period (adult derivation) and (2) as observed weighted average of daily straining scores during that period. Daily straining score was the average of non-missing morning and/or evening assessments of straining score from the SBMs reported by the participants on that specific day. LSM and SE were calculated using ANCOVA method.

  4. Change From Baseline (CFB) in 4-week Abdominal Bloating Daytime Symptoms Based on Evening Assessment

    Time frame · Baseline (14-day prior to randomization) to Week 4

    Registry description

    Participants recorded their assessment of abdominal bloating in the evening eDiary. Participants answered the question: How big and full did your tummy feel? on a scale, where: 0=none, 1=a tiny bit, 2=a little, 3=medium or 4=very, with a higher score indicating more severe bloating. Baseline value was the average of values collected 14 days before randomization. The 4-week daytime abdominal bloating symptoms were calculated as the average of non-missing scores reported in the evening eDiary during the treatment period. Change from Baseline was calculated as the 4-week daytime abdominal bloating score during the treatment period - daytime abdominal bloating score at baseline. A negative change from Baseline indicates improvement. LSM and SE were calculated using ANCOVA method.

  5. Change From Baseline (CFB) in 4-week Overall Complete Spontaneous Bowel Movement Frequency Rate (CSBM/Week) During the Treatment Period

    Time frame · Baseline (14-day prior to randomization and up to randomization) to Week 4

    Registry description

    SBM was defined as a BM that occurred in the absence of laxative, suppository, or enema use on the calendar day of the BM or the calendar day before the BM. A CSBM was an SBM that was associated with a sense of complete evacuation. Participants recorded their assessment of the sensation of incomplete evacuation for each BM in the morning and evening eDiary. The 4-week overall CSBM frequency rate was calculated as \[total number of CSBMs in the analysis period/number of days in the analysis period\]\*7). Baseline value was based on values collected 14 days before randomization and up to randomization. Change from Baseline was calculated as the CSBM frequency rate during the 4-week treatment period - CSBM frequency rate at baseline. A positive change from Baseline indicates improvement. LSM and SE were calculated using ANCOVA method.

  6. Change From Baseline in 4-week Fecal Incontinence Daytime Symptoms Based on Evening Assessment

    Time frame · Baseline (14-day prior to randomization) to Week 4

    Registry description

    Participants recorded the presence of incontinence episodes in daytime daily since pre-treatment period (14-day prior to randomization) in the evening eDiary for participants randomized following protocol amendment #3. The 4-week daytime fecal incontinence was calculated as the mean of non-missing participant scores reported in the evening eDiary during the Treatment Period. Baseline value was the average of values collected 14 days before randomization. Change from Baseline was calculated as the 4-week fecal incontinence daytime symptoms during the treatment period - fecal incontinence daytime symptoms at baseline. A negative change from Baseline indicates improvement. No data is reported for LIN 145 μg as it was an exploratory arm group.

Posted results

Values are shown as posted at ClinicalTrials.gov, with their units. PepBank has not converted, pooled or compared them.

Primary outcome results

Primary outcomeLeast squares mean· Baseline (14-day prior to randomization and up to randomization) to Week 4

Change From Baseline (CFB) in 4-week Overall Spontaneous Bowel Movement (SBM) Frequency Rate During the Treatment Period

GroupValue (SBMs/week)Spread
Placebo2.0000.394
LIN Dose A (9 ug or 18 ug)1.4120.422
LIN Dose B (18 ug or 36 ug)1.8140.397
LIN Dose C (36 ug or 72 ug)2.3640.403
Secondary and other outcome results(6)
Secondary outcomeLeast squares mean· Baseline (14-day prior to randomization) to Week 4

Change From Baseline (CFB) in 4-week Daytime Abdominal Pain

GroupValue (score on a scale)Spread
Placebo-0.2910.102
LIN Dose A (9 ug or 18 ug)-0.3330.108
LIN Dose B (18 ug or 36 ug)-0.2890.102
LIN Dose C (36 ug or 72 ug)-0.1710.103
Secondary outcomeLeast squares mean· Baseline (14-day prior to randomization and up to randomization) to Week 4

Change From Baseline (CFB) in 4-week Stool Consistency

GroupValue (score on a scale)Spread
Placebo0.6900.174
LIN Dose A (9 ug or 18 ug)0.6410.177
LIN Dose B (18 ug or 36 ug)0.6520.174
LIN Dose C (36 ug or 72 ug)1.0460.172
Secondary outcomeLeast squares mean· Baseline (14-day prior to randomization and up to randomization) to Week 4

Change From Baseline (CFB) in 4-week of Severity of Straining

GroupValue (score on a scale)Spread
Placebo-0.6570.145
LIN Dose A (9 ug or 18 ug)-0.7100.150
LIN Dose B (18 ug or 36 ug)-0.7780.147
LIN Dose C (36 ug or 72 ug)-0.8930.145
Secondary outcomeLeast squares mean· Baseline (14-day prior to randomization) to Week 4

Change From Baseline (CFB) in 4-week Abdominal Bloating Daytime Symptoms Based on Evening Assessment

GroupValue (score on a scale)Spread
Placebo-0.3140.104
LIN Dose A (9 ug or 18 ug)-0.2660.110
LIN Dose B (18 ug or 36 ug)-0.2870.104
LIN Dose C (36 ug or 72 ug)-0.2750.105
Secondary outcomeLeast squares mean· Baseline (14-day prior to randomization and up to randomization) to Week 4

Change From Baseline (CFB) in 4-week Overall Complete Spontaneous Bowel Movement Frequency Rate (CSBM/Week) During the Treatment Period

GroupValue (CSBMs/week)Spread
Placebo1.2400.308
LIN Dose A (9 ug or 18 ug)0.8150.328
LIN Dose B (18 ug or 36 ug)1.0050.309
LIN Dose C (36 ug or 72 ug)1.3200.314
Secondary outcomeMean· Baseline (14-day prior to randomization) to Week 4

Change From Baseline in 4-week Fecal Incontinence Daytime Symptoms Based on Evening Assessment

GroupValue (incontinence episodes)Spread
Placebo-0.0280.081
LIN Dose A (9 ug or 18 ug)-0.0250.083
LIN Dose B (18 ug or 36 ug)-0.0090.067
LIN Dose C (36 ug or 72 ug)0.1700.298

Adverse events, as posted

Adverse events as posted: participants affected out of participants at risk, by group
GroupDeathsSerious eventsOther events
PlaceboParticipants aged 6 to 11 or 12 to 17 years received matching placebo linaclotide (LIN), 30 minutes before evening meal, once daily for 4 weeks. Administered as liquid oral solution for participants 6 to 11 years of age and solid oral capsule or liquid oral solution for participants 12 to 17 years of age.0 / 410 / 413 / 41
LIN Dose A (9 ug or 18 ug)Participants aged 6 to 11 years with weight 18 to \<35 kg received LIN 9 ug, oral solution, 30 minutes before evening meal, once daily for 4 weeks. Participants aged 6 to 11 years with weight ≥35 kg received LIN 18 ug, oral solution, 30 minutes before evening meal, once daily for 4 weeks. Participants aged 12 to 17 years received LIN 18 ug, oral solution or solid capsules, 30 minutes before evening meal, once daily for 4 weeks0 / 361 / 361 / 36
LIN Dose B (18 ug or 36 ug)Participants aged 6 to 11 years with weight 18 to \<35 kg received LIN 18 ug, oral solution, 30 minutes before evening meal, once daily for 4 weeks. Participants aged 6 to 11 years with weight ≥35 kg received LIN 36 ug, oral solution, 30 minutes before evening meal, once daily for 4 weeks. Participants aged 12 to 17 years received LIN 36 ug, oral solution or solid capsules, 30 minutes before evening meal, once daily for 4 weeks.0 / 410 / 413 / 41
LIN Dose C (36 ug or 72 ug)Participants aged 6 to 11 years with weight 18 to \<35 kg received LIN 36 ug, oral solution, 30 minutes before evening meal, once daily for 4 weeks. Participants aged 6 to 11 years with weight ≥35 kg received LIN 72 ug, oral solution, 30 minutes before evening meal, once daily for 4 weeks. Participants aged 12 to 17 years received LIN 72 ug, oral solution or solid capsules, 30 minutes before evening meal, once daily for 4 weeks.0 / 390 / 3910 / 39
LIN 145 µgParticipants aged 12 to 17 years received LIN 145 ug, oral solution or solid capsules, 30 minutes before evening meal, once daily for 4 weeks.0 / 161 / 164 / 16

Each cell reads participants affected / participants at risk, as the registry posted them.

Registry data comes from ClinicalTrials.gov. Study results come from studies, not from the registry. How PepBank works

Studies0

Studies that cite this trial.

No study cites this trial.

Eligibility

Who could join, as posted.

Sex
All
Age
from 6 Years up to 17 Years
Healthy volunteers
Not accepted
Inclusion and exclusion criteria, as posted
Inclusion Criteria: * Participant weighs at least 18 kg (kilograms) (39.7 lbs) * Participant meets modified Rome III criteria for child/adolescent FC: For at least 2 months before the Screening Visit, the participant has had 2 or fewer defecations (with each defecation occurring in the absence of any laxative, suppository, or enema use during the preceding 24 hours) in the toilet per week. In addition, at least once per week, patient meets 1 or more of the following: * a) History of retentive posturing or excessive volitional stool retention * b) History of painful or hard bowel movements (BMs) * c) Presence of a large faecal mass in the rectum * d) History of large diameter stools that may obstruct the toilet * e) At least one episode of fecal incontinence per week * Participant is willing to discontinue any laxatives used before the Pretreatment Visit in favor of the protocol-permitted rescue medicine * Participant has an average of fewer than 3 spontaneous BMs (SBMs) per week during the 14 days before the randomization day and up to the randomization. An SBM is defined as a BM that occurs in the absence of laxative, enema, or suppository use on the calendar day of the BM or the calendar day before the BM * Participant or participant/guardian/legally authorized representative (LAR) or caregiver is compliant with electronic diary (eDiary) by completing both the morning and evening assessments for 10 out of the 14 days immediately preceding the Randomization Visit Exclusion Criteria: * Participant meets Rome III criteria for Child/Adolescent irritable bowel syndrome (IBS): At least once per week for at least 2 months before the Screening Visit, the participant has experienced abdominal discomfort (an uncomfortable sensation not described as pain) or pain associated with 2 or more of the following at least 25% of the time: * 1\. Improvement with defecation * 2\. Onset associated with a change in frequency of stool * 3\. Onset associated with a change in form (appearance) of stool * Participant reports having more than 1 loose, mushy stool (eDiary-recorded stool consistency of 6 on the Pediatric Bristol Stool Form Scale \[p-BSFS\]) or any watery stool (eDiary-recorded stool consistency of 7 on the p-BSFS) with any SBM that occurred in the absence of laxative use on the calendar day of the BM or the calendar day before the BM during the 14 days before the randomization day and up to the randomization * Select medical history or conditions that may be related to other causes of constipation or may interfere with safety and efficacy analyses * Participant has required manual or hospital-based disimpassion any time prior to randomization * Participant is unable to tolerate the placebo during the Screening Period

PepBank is a research reference. Talk to a doctor before you use any peptide.